ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

ObjectiveTo investigate the relationship between Excision repair cross-complementation 1 (ERCC1) expression, clinicopathological features, and breast cancer prognosis in patients treated with trastuzumab. Further, we aim to explore the immune status of ERCC1 in breast cancer.MethodsThe data were ret...

Full description

Bibliographic Details
Main Authors: Yilun Li, Xiaomei Liao, Li Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
breast cancer
excision repair cross-complementary gene 1
human epidermal growth factor receptor-2
prognosis
clinicopathological feature
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.955719/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.955719/full

Similar Items